1. Media & Marketing

Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing

Written by Posted on Less than 0 min read

Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds

John discusses how the new maximum fair prices (MFPs) published by the Centers for Medicaid & Medicare Services (CMS) will affect medication affordability, formulary negotiations, evidence-based strategies, and other aspects of the market.

To learn more, register for CoverMyMeds’ October 10, 2024, webinar: The Inflation Reduction Act: What to Watch Following the First Round of Negotiations.

Read on for John’s Insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2032: Four Takeaways from the New Government Forecasts

The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest projections for U.S. spending on healthcare. (See links below.) These data provide the latest official look at how the Inflation Reduction Act (IRA) will affect U.S. healthcare spending. As you will see below, CMS projects that outpatient prescription drugs dispensed […]
2 min read
0
  1. Channel: Drug

Drug Channels News Roundup, April 2024: CVS’s Humira Strategy, White Bagging “Savings,” IRA vs. Part D Plans, Walgreens Specialty Update, Pharmacies vs. GoodRx, and Oncology Fun

April is over, so it’s time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? My $0.02 on how Medicare Part D plans will react to the Inflation Reduction Act Walgreens’ unexpected specialty pharmacy strength […]
2 min read
0
  1. Trends & External Forces

Digital as a Disguise: Beware the Illusion of an Automated Hub Experience

Today’s guest post comes from Rebecca Cotton, Executive Director of Strategy & Product Innovation at Cardinal Health™ Sonexus™ Access and Patient Support Rebecca discusses the essential features biopharmaceutical manufacturers should seek in a digital hub that will help patients get their therapies faster. She argues that the most effective hub balances automation with the still-relevant […]
2 min read
0
  1. Trends & External Forces

Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs (rerun)

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The article below highlights an underappreciated consequence of the Inflation Reduction Act’s inflation rebates for Medicare Part B drugs. Last night, I posted an updated analysis showing that the volatility […]
3 min read
0
  1. Trends & External Forces

The Inflation Reduction Act: 10 Predictions About Market Access and Drug Channels

Like it or not, the Centers for Medicare & Medicaid Services (CMS) is barreling ahead with its implementation of the Inflation Reduction Act of 2022 (IRA). Last Friday was the last day to submit comments on CMS’s initial guidance on the drug price negotiation program. The IRA will alter many crucial aspects of the Medicare […]
2 min read
0
  1. Media & Marketing

The Economics of Copay Accumulators, Maximizers, and Alternative Funding Programs (Video)

In my most recent video webinar, I explored how plans and PBMs are turning to novel—and highly controversial—benefit design tools that access manufacturers’ patient support spending: copay accumulators, maximizers, and alternative funding programs. In the video excerpt below, I describe these new approaches that plans offset specialty drug expenses. I then follow the dollar to […]
2 min read
0
  1. Media & Marketing

Mark Cuban: Five Ways that Big PBMs Hurt U.S. Healthcare–And How We Can Fix It (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. The webinar begins at 12:00 PM ET. Click here to see the original post from March 2024. Today’s guest post comes from Mark Cuban, co-founder of the Mark Cuban Cost Plus […]
2 min read
0
  1. Technology & Innovation

Transforming Medication Access with the Next Generation of Patient Support Services

Today’s guest post comes from Kelly Martin, Vice President of Product Management at CoverMyMeds. Kelly discusses the obstacles that patients face when attempting to access, afford, and adhere to specialty therapies. She describes how CoverMyMeds improves the patient experience by blending technology with human expertise and connection. Click here to learn about CoverMyMed’s next-generation patient […]
2 min read
0
  1. Department: HBC

Independents Outshine PBMs in Manufacturers’ Exclusive Specialty Pharmacy Networks (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Click here to see the original post from April 2024. Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 Specialty Pharmacies of 2023: […]
2 min read
0
  1. Corporate Finance

Rethinking Financial Services in Biopharma Patient Affordability Programs

Today’s guest post comes from Bob Raffo, Senior Vice President of Financial Services & Strategic Commercial Development at Cencora. Bob discusses the challenges faced by patient affordability programs managed by third-party vendors. He explains three ways that biopharma companies can benefit by working with a financial services provider specializing in patient affordability programs. Click here […]
2 min read
0
  1. Channel: Drug

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. Click here to see the original post from September 2023. One update: CVS Caremark’s 2024 formulary for patient-administered autoimmune products prefers: Humira Hyrimoz (the high WAC Sandoz biosimilar) adalimumab-adaz (the unbranded, low WAC Sandoz biosimilar) Perhaps coincidentally, […]
2 min read
0
  1. Media & Marketing

PBMs and the Battle Over Patient Support Funds:Accumulators, Maximizers, and Alternative Funding (NEW Live Video Webinar)

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for a new video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding This event will be broadcast live on Friday, June 23, 2023, from 12:00 p.m. to 1:30 […]
5 min read
0
  1. Data & Insights

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers

In case you haven’t noticed, private equity firms have displaced hospitals and health systems as the major acquirers of community oncology practices. These financial firms have assembled significant oncology practice management companies that are primed for purchase by drug channel participants. Below, I review recent M&A trends and then examine the strategic objectives behind the […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, September 2023: PBM Profits, Specialty Rx Markups, CVS Spending Trends, Pharmacy Pricing Secrets, and Deductibles 101

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch: A must-read report on hidden sources of PBMs’ profits How generic drugs drive specialty pharmacy profits CVS Health’s unadvertised 2022 drug trend report A shocking look at how PBMs set prescription prices Plus, Dr. […]
2 min read
0
  1. Trends & External Forces

Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs

Contrary to what you may have heard, the Inflation Reduction Act’s (IRA) inflation rebates for Medicare Part B drugs do not always save money for seniors. As we document below, a growing share of Part B drugs have inflation-adjusted coinsurance rates that have been increasing, not declining. In many cases, the coinsurance rate declines only […]
2 min read
0
  1. Channel: Drug

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. Below, we review the 18 products competing with Humira—including four private-label […]
2 min read
0
  1. Trends & External Forces

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. We have identified nearly 1,800 dispensing sites with specialty pharmacy accreditation—about 40% of which are owned by hospitals, physician practices, and other healthcare providers. Alas, specialty pharmacies owned by the three largest […]
2 min read
0
  1. Data & Insights

Copay Comes Full Circle: An Industry Ready for Disruption

Today’s guest post comes from Logan Melchione, VP of Patient Affordability at Paysign. Logan discusses the evolution of patient support programs. She then outlines how these programs must evolve to stay relevant and valuable. To request an analysis of your copay savings program and learn more about Paysign’s patient affordability solutions, contact [email protected] or visit […]
2 min read
0
  1. Department: HBC

Hospitals Are Relying More on PBMs to Manage Manufacturers’ 340B Contract Pharmacy Restrictions: DCI’s 2024 Market Analysis (rerun)

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2024. The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market […]
3 min read
0
  1. Media & Marketing

A Reality Check on That Blue Shield of California Announcement

Last week, Anna Matthews of The Wall Street Journal scored a market-moving scoop with her story about Blue Shield of California’s decision to ditch CVS Health’s Caremark pharmacy benefit manager (PBM) in favor of five separate vendors. ICYMI: A Big Health Insurer Is Ripping Up the Playbook on Drug Pricing I commend Blue Shield of […]
2 min read
0
Next